C4 Therapeutics Corp (CCCC) Long-Term Debt to Capital Ratio

The price trend for C4 Therapeutics, Inc. (CCCC) demonstrates the 0.20 indicator. The business is based on creating advanced tools for the degradation of oncogenic proteins in the treatment of blood and solid tumors. The team brings together leading chemists attracted by state-of-the-art equipment and stock options. The current strategy is focused on the global expansion of PROTAC therapy trials in collaboration with the world's largest pharmaceutical behemoths.

C4 Therapeutics, Inc. (CCCC) is developing the innovative TORPEDO platform for targeted protein degradation in the treatment of oncological diseases. The long-term leverage ratio measures the proportion of debt with a maturity of over one year within the capital structure, allowing for an assessment of the risk of over-leverage or the underutilization of financial leverage for expansion, a trend captured by the dynamics of the long-term debt-to-equity ratio.